-
Je něco špatně v tomto záznamu ?
Telomere length in peripheral blood cells of germline TP53 mutation carriers is shorter than that of normal individuals of corresponding age
M. Trkova, K. Prochazkova, V. Krutilkova, D. Sumerauer, Z. Sedlacek
Jazyk angličtina Země Spojené státy americké
Typ dokumentu srovnávací studie
NLK
Wiley Online Library (archiv)
od 1948-01-01 do 2012-12-31
Wiley Free Content
od 1996 do Před 1 rokem
PubMed
17567834
DOI
10.1002/cncr.22834
Knihovny.cz E-zdroje
- MeSH
- detekce genetických nosičů MeSH
- dítě MeSH
- dospělí MeSH
- financování organizované MeSH
- genetická predispozice k nemoci MeSH
- lidé MeSH
- Liův-Fraumeniho syndrom genetika krev MeSH
- messenger RNA genetika metabolismus MeSH
- nádorový supresorový protein p53 genetika MeSH
- nádory genetika krev MeSH
- polymerázová řetězová reakce s reverzní transkripcí MeSH
- telomery fyziologie MeSH
- věk při počátku nemoci MeSH
- zárodečné mutace genetika MeSH
- Check Tag
- dítě MeSH
- dospělí MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- srovnávací studie MeSH
BACKGROUND: A decrease in the age at cancer onset and increase in cancer incidence in successive generations in Li-Fraumeni syndrome (LFS) families with germline TP53 mutations have been previously described. In the current study a possible relation was analyzed between telomere length and cancer onset in TP53 mutation carriers. METHODS: Telomere length was measured using real-time quantitative polymerase chain reaction (PCR) in 20 carriers of germline TP53 mutations and in 83 unrelated healthy individuals. According to the age at blood sampling, patients and controls were divided into 2 age groups, children and adults. Telomere length was correlated to TP53 mutation status and telomere shortening in patients to the age at cancer onset. A t-test and linear regression were used to analyze the data. RESULTS: Compared with healthy controls, telomere length was significantly shorter both in the child (P = .001) and adult (P = .034) germline T53 mutation carriers. Although a statistically significant correlation between telomere shortening and the age at cancer onset was not observed, there was a trend of shorter telomeres in mutation carriers affected in childhood compared with those affected later in life. Neither cancer therapy nor sex differences were likely to affect the results. CONCLUSIONS: The findings suggest a possible link between the carriership of a germline TP53 mutation, telomere length, predisposition to early-onset cancer, and anticipation in LFS. (c) 2007 American Cancer Society.
Citace poskytuje Crossref.org
- 000
- 03342naa 2200469 a 4500
- 001
- bmc10010416
- 003
- CZ-PrNML
- 005
- 20240125152605.0
- 008
- 100430s2007 xxu e eng||
- 009
- AR
- 024 __
- $a 10.1002/cncr.22834 $2 doi
- 035 __
- $a (PubMed)17567834
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Trková, Marie $7 xx0164107
- 245 10
- $a Telomere length in peripheral blood cells of germline TP53 mutation carriers is shorter than that of normal individuals of corresponding age / $c M. Trkova, K. Prochazkova, V. Krutilkova, D. Sumerauer, Z. Sedlacek
- 314 __
- $a Department of Biology and Medical Genetics, Charles University 2nd Medical School and University Hospital Motol, Prague, Czech Republic. marie.trkova@lfmotol.cuni.cz
- 520 9_
- $a BACKGROUND: A decrease in the age at cancer onset and increase in cancer incidence in successive generations in Li-Fraumeni syndrome (LFS) families with germline TP53 mutations have been previously described. In the current study a possible relation was analyzed between telomere length and cancer onset in TP53 mutation carriers. METHODS: Telomere length was measured using real-time quantitative polymerase chain reaction (PCR) in 20 carriers of germline TP53 mutations and in 83 unrelated healthy individuals. According to the age at blood sampling, patients and controls were divided into 2 age groups, children and adults. Telomere length was correlated to TP53 mutation status and telomere shortening in patients to the age at cancer onset. A t-test and linear regression were used to analyze the data. RESULTS: Compared with healthy controls, telomere length was significantly shorter both in the child (P = .001) and adult (P = .034) germline T53 mutation carriers. Although a statistically significant correlation between telomere shortening and the age at cancer onset was not observed, there was a trend of shorter telomeres in mutation carriers affected in childhood compared with those affected later in life. Neither cancer therapy nor sex differences were likely to affect the results. CONCLUSIONS: The findings suggest a possible link between the carriership of a germline TP53 mutation, telomere length, predisposition to early-onset cancer, and anticipation in LFS. (c) 2007 American Cancer Society.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a věk při počátku nemoci $7 D017668
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a genetická predispozice k nemoci $7 D020022
- 650 _2
- $a zárodečné mutace $x genetika $7 D018095
- 650 _2
- $a detekce genetických nosičů $7 D006580
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a Liův-Fraumeniho syndrom $x genetika $x krev $7 D016864
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a nádory $x genetika $x krev $7 D009369
- 650 _2
- $a messenger RNA $x genetika $x metabolismus $7 D012333
- 650 _2
- $a polymerázová řetězová reakce s reverzní transkripcí $7 D020133
- 650 _2
- $a telomery $x fyziologie $7 D016615
- 650 _2
- $a nádorový supresorový protein p53 $x genetika $7 D016159
- 650 _2
- $a financování organizované $7 D005381
- 655 _2
- $a srovnávací studie $7 D003160
- 700 1_
- $a Procházková, Kamila. $7 _AN051942
- 700 1_
- $a Krutílková, Věra $7 xx0156528
- 700 1_
- $a Sumerauer, David $7 xx0105538
- 700 1_
- $a Sedláček, Zdeněk, $d 1960- $7 skuk0005184
- 773 0_
- $t Cancer $w MED00001031 $g Roč. 110, č. 3 (2007), s. 694-702 $x 0008-543X
- 910 __
- $a ABA008 $b x $y 8 $z 0
- 990 __
- $a 20100503140203 $b ABA008
- 991 __
- $a 20240125152559 $b ABA008
- 999 __
- $a ok $b bmc $g 724097 $s 587231
- BAS __
- $a 3
- BMC __
- $a 2007 $b 110 $c 3 $d 694-702 $i 0008-543X $m Cancer $n Cancer $x MED00001031
- LZP __
- $a 2010-B2/dkme